A LinkedIn post from Orasis Pharmaceuticals highlights a patient testimonial from Suzanne, a nurse practitioner and aesthetic injector managing presbyopia. The post describes how she reports gaining “visual freedom” and reduced reliance on reading glasses after being prescribed the company’s presbyopia eye drop. Read more.

Orasis Pharmaceuticals announced new clinical data demonstrating that Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% is pupil selective, significantly reducing pupil diameter without a statistically significant change in ciliary muscle response in presbyopic eyes. Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals, said “We believe this further illustrates why formulation matters and why the concentration-dependent effects demonstrated by Qlosi reinforc

Orasis Pharmaceuticals, an ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities, has announced the availability of Starter Packs of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4% to broaden access for patients seeking a flexible option to manage their presbyopia and allow greater first-hand experience for eye care professionals (ECPs). The availability of Qlosi Starter Packs marks the next phase of Qlosi's successful commercial e

Pupil size reduction remained consistent through day 8. More eyes improved from day 1 to day 8. These results suggest neuroadaptation with Qlosi. Qlosi demonstrated consistent pupil size reduction and increasing rates of near visual acuity in patients with presbyopia over 8 days, according to a study. Read more.